ABSTRACT
Mood instability (MOOD) is a transdiagnostic phenomenon with a prominent neurobiological basis. Recent genome-wide association studies found significant positive genetic correlation between MOOD and major depression (DEP) and weak correlations with other psychiatric disorders. We investigated the polygenic overlap between MOOD and psychiatric disorders beyond genetic correlation to better characterize putative shared genetic determinants. Summary statistics for schizophrenia (SCZ, n=105,318), bipolar disorder (BIP, n=413,466), DEP (n=450,619), attention-deficit hyperactivity disorder (ADHD, n=53,293) and MOOD (n=363,705), were analysed using the bivariate causal mixture model and conjunctional false discovery rate methods to estimate the proportion of shared variants influencing MOOD and each disorder, and identify jointly associated genomic loci. MOOD correlated positively with all psychiatric disorders, but with wide variation in strength (rg=0.10-0.62). Of 10.4K genomic variants influencing MOOD, 4K-9.4K were estimated to influence psychiatric disorders. MOOD was jointly associated with DEP at 163 loci, SCZ at 110, BIP at 60 and ADHD at 25, with consistent genetic effects in independent samples. Fifty-three jointly associated loci were overlapping across two or more disorders (transdiagnostic), seven of which had discordant effect directions on psychiatric disorders. Genes mapped to loci associated with MOOD and all four disorders were enriched in a single gene-set, “synapse organization”. The extensive polygenic overlap indicates shared molecular underpinnings across MOOD and psychiatric disorders. However, distinct patterns of genetic correlation and effect directions of shared loci suggest divergent effects on corresponding neurobiological mechanisms which may relate to differences in the core clinical features of each disorder.
Competing Interest Statement
O.A.A. has received speakers honorarium from Lundbeck and is a consultant for Healthlytix. A.M.D. is a founder of and holds equity interest in CorTechs Labs and serves on its scientific advisory board. He is also a member of the Scientific Advisory Board of Healthlytix and receives research funding from General Electric Healthcare (GEHC). The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. Remaining authors report no financial relationships with commercial interests.
Funding Statement
We gratefully acknowledge support from the American National Institutes of Health (NS057198, EB00790), the Research Council of Norway (229129, 213837, 223273), the South-East Norway Regional Health Authority (2017-112), KG Jebsen Stiftelsen (SKGJ-MED-008) and the PGC US Norway Collaboration (RCN# 248980). This project has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No 847776.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Norwegian Institutional Review Board: Regional Committees for Medical and Health Research Ethics (REC) South-East Norway evaluated the current protocol and found that no additional ethical approval was required because no individual data were used.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All PGC data are available at https://www.med.unc.edu/pgc/download-results/, schizophrenia meta-analysis of PGC and CLOZUK datasets at https://walters.psycm.cf.ac.uk/, height at https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files, and FinnGen at https://www.finngen.fi/en/access_results. Full GWAS summary statistics for the 23andMe depression dataset will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Interested investigators should email dataset-request{at}23andme.com and reference this paper for more information. Summary statistics for mood instability are available upon request by contacting the corresponding author of the original mood instability GWAS. The code for all analyses can be accessed at https://github.com/precimed.
https://www.med.unc.edu/pgc/download-results/
https://walters.psycm.cf.ac.uk/
https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files
